<DOC>
	<DOCNO>NCT02745769</DOCNO>
	<brief_summary>The main purpose study evaluate safety ramucirumab combination target agent participant advance cancer .</brief_summary>
	<brief_title>A Study Advanced Cancers Using Ramucirumab ( LY3009806 ) Other Targeted Agents</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Study Arm 1 : histopathologically confirm advanced metastatic colorectal cancer , exclude primary tumor appendiceal origin least 1 measurable lesion assessable radiological imaging . Tumor lesion locate previously irradiate area consider measureable progression demonstrate lesion receive prior secondline treatment oxaliplatin and/or irinotecan , licensed/standardofcare therapy available . If participant RAS wild type colorectal cancer , also must receive prior treatment epidermal growth factor receptor monoclonal antibody Study Arm 2 pathologically confirm mantle cell lymphoma ( MCL ) , ( ) measurable nodal disease positron emission tomography compute tomography ( PETCT ) per Lugano classification . Prior enrollment , pathology must review confirmed investigational site participant enter MCL relapse refractory ( ) firstline combination chemotherapy without stem cell transplant ( b ) least 1 locally available therapy provide newly obtain tumor tissue sample . Tumor tissue biopsy may take surgical resection , core needle biopsy , fine needle biopsy All Study Arms : receive previous systemic therapy ( include investigational agent ) target program cell death protein 1 ( PD1 ) / PD1 ligand ( PDL 1 ) PD1/PDL2 signal pathway . Prior therapy immune checkpoint inhibitor , include limited , antiCD137 antibody anticytotoxic Tlymphocyteassociated antigen4 antibody , permit adequate organ function , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit discontinue previous treatment cancer recover acute effect therapy , less equal Grade 2 neuropathy nonserious nonlifethreatening toxicity alopecia , alter taste , nail change performance status 0 1 Eastern Cooperative Oncology Group scale men woman must agree use effective method contraception study least 3 month post last dose study drug administration . Women childbearing potential must negative serum urine pregnancy test screen treatment cycle , respectively Study Arm 1 serious illness medical condition include , limited , follow : active uncontrolled clinically serious infection ; inadequate biliary drainage evidence unresolved biliary obstruction Study Arm 2 serious illness medical condition include , limited , follow : receive autologous stem cell transplant within 75 day prior initial dose study drug ; receive allogeneic stem cell transplant ; active uncontrolled clinically serious infection , include chronic viral hepatitis All Arms : prior concurrent malignancy , inclusive hematologic , primary brain tumor , sarcoma , solid tumor , unless complete remission therapy minimum 5 year active gastrointestinal ( GI ) disease characterize inflammatory bowel disease , malabsorption syndrome , frequent Grade 2 diarrhea pregnant breastfeeding previously document brain metastasis , leptomeningeal disease , uncontrolled spinal cord compression experience follow : major surgical procedure , significant traumatic injury , nonhealing wound , peptic ulcer , bone fracture less equal 28 day prior enrollment , placement subcutaneous venous access device le equal 7 day prior first dose study treatment unless procedure low risk bleed judgment investigator elective plan major surgery course trial know allergy hypersensitivity reaction treatment component uncontrolled hypertension experience arterial thromboembolic event within 6 month prior enrollment experience Grade 3 4 venous thromboembolic event consider investigator life threaten symptomatic adequately treated anticoagulation therapy , within 6 month prior enrollment history GI perforation and/or fistula within 6 month prior enrollment experience bleed episode consider lifethreatening , Grade 3 4 GI/variceal bleed episode 3 month prior enrollment require transfusion endoscopic operative intervention congestive heart failure poorly control cardiac arrhythmia per New York Heart Association Class IIIV heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>